Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS); and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03976375
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Active, not recruiting
Phase Phase 3
Start date June 26, 2019
Completion date September 18, 2024

See also
  Status Clinical Trial Phase
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Not yet recruiting NCT05985330 - Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
Recruiting NCT05013450 - Dupilumab_Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT05984277 - A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. Phase 3
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT05675683 - Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
Active, not recruiting NCT02411448 - A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Phase 3
Recruiting NCT04410796 - Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Phase 2
Recruiting NCT03300115 - Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC Phase 2
Recruiting NCT05635708 - A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Phase 2
Terminated NCT03265080 - A Study of ADXS-NEO Expressing Personalized Tumor Antigens Phase 1
Active, not recruiting NCT05226598 - Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Phase 3
Withdrawn NCT02639234 - Vigilâ„¢ + Nivolumab in Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05364073 - Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations Phase 1
Completed NCT03926260 - Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA N/A
Recruiting NCT05546905 - A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Recruiting NCT06212752 - A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension Phase 3
Recruiting NCT05607550 - Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) Phase 3
Recruiting NCT03976856 - Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib Phase 1